BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marin JJG, Lozano E, Herraez E, Asensio M, Di Giacomo S, Romero MR, Briz O, Serrano MA, Efferth T, Macias RIR. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1444-1453. [PMID: 28600147 DOI: 10.1016/j.bbadis.2017.06.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Herraez E, Romero MR, Macias RIR, Monte MJ, Marin JJG. Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2020;9:211-214. [PMID: 32355682 DOI: 10.21037/hbsn.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Suksawat M, Klanrit P, Phetcharaburanin J, Namwat N, Khuntikeo N, Titapun A, Jarearnrat A, Sa-Ngiamwibool P, Techasen A, Loilome W. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. PLoS One 2019;14:e0222140. [PMID: 31504065 DOI: 10.1371/journal.pone.0222140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen C, Nelson LJ, Ávila MA, Cubero FJ. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells 2019;8:E1172. [PMID: 31569444 DOI: 10.3390/cells8101172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
4 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Wang X, Zheng Y, Bao C, Zhong G, Liu S, Wiradharma N, Fan W, Yang YY, Wang X, Huang Y. Branched α-helical peptides enhanced antitumor efficacy and selectivity. Biomater Sci 2020;8:6387-94. [PMID: 33029595 DOI: 10.1039/d0bm00629g] [Reference Citation Analysis]
6 Babic T, Dinic J, Buric SS, Hadzic S, Pesic M, Radojkovic D, Rankov AD. Comparative toxicity evaluation of targeted anticancer therapeutics in embryonic zebrafish and sea urchin models. Acta Biologica Hungarica 2018;69:395-410. [DOI: 10.1556/018.69.2018.4.3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Alonso-Peña M, Espinosa-Escudero RA, Soto-Muñiz M, Sanchon-Sanchez P, Sanchez-Martin A, Marin JJ. Role of transportome in the pharmacogenomics of hepatocellular carcinoma and hepatobiliary cancer. Pharmacogenomics 2019;20:957-70. [PMID: 31486734 DOI: 10.2217/pgs-2019-0033] [Reference Citation Analysis]
8 Bekric D, Neureiter D, Ritter M, Jakab M, Gaisberger M, Pichler M, Kiesslich T, Mayr C. Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review. J Clin Med 2020;9:E1200. [PMID: 32331331 DOI: 10.3390/jcm9041200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Massa A, Varamo C, Vita F, Tavolari S, Peraldo-Neia C, Brandi G, Rizzo A, Cavalloni G, Aglietta M. Evolution of the Experimental Models of Cholangiocarcinoma. Cancers (Basel) 2020;12:E2308. [PMID: 32824407 DOI: 10.3390/cancers12082308] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
10 Jones O, Cheng X, Murthy SRK, Ly L, Zhuang T, Basadonna G, Keidar M, Canady J. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro. Sci Rep 2021;11:8967. [PMID: 33903679 DOI: 10.1038/s41598-021-88451-w] [Reference Citation Analysis]
11 Taghvaei S, Sabouni F, Minuchehr Z. Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort. Front Pharmacol 2021;12:700454. [PMID: 34276383 DOI: 10.3389/fphar.2021.700454] [Reference Citation Analysis]
12 Klungsaeng S, Kukongviriyapan V, Prawan A, Kongpetch S, Senggunprai L. Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. Am J Chin Med 2020;48:1475-89. [PMID: 32907364 DOI: 10.1142/S0192415X2050072X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Lozano E, Asensio M, Perez-Silva L, Banales JM, Briz O, Marin JJG. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression. Hepatology 2020;72:949-64. [PMID: 31863486 DOI: 10.1002/hep.31088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Macias RIR, Muñoz-Bellvís L, Sánchez-Martín A, Arretxe E, Martínez-Arranz I, Lapitz A, Gutiérrez ML, La Casta A, Alonso C, González LM, Avila MA, Martinez-Chantar ML, Castro RE, Bujanda L, Banales JM, Marin JJG. A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1433. [PMID: 32486461 DOI: 10.3390/cancers12061433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
15 Yang Y, Li J, Yao L, Wu L. Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR. Front Cell Dev Biol 2021;9:710721. [PMID: 34805140 DOI: 10.3389/fcell.2021.710721] [Reference Citation Analysis]
16 Balasubramanian B, Venkatraman S, Janvilisri T, Suthiphongchai T, Jitkaew S, Sripa J, Tohtong R. RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach. Pharmaceuticals (Basel) 2021;14:898. [PMID: 34577598 DOI: 10.3390/ph14090898] [Reference Citation Analysis]
17 Briz O, Perez-Silva L, Al-Abdulla R, Abete L, Reviejo M, Romero MR, Marin JJG. What "The Cancer Genome Atlas" database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs. Expert Opin Drug Metab Toxicol 2019;15:577-93. [PMID: 31185182 DOI: 10.1080/17425255.2019.1631285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
18 Jansen H, Pape UF, Utku N. A review of systemic therapy in biliary tract carcinoma. J Gastrointest Oncol 2020;11:770-89. [PMID: 32953160 DOI: 10.21037/jgo-20-203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Permpoon U, Khan F, Vadevoo SMP, Gurung S, Gunassekaran GR, Kim MJ, Kim SH, Thuwajit P, Lee B. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor. Mol Pharm 2020;17:4077-88. [PMID: 32881535 DOI: 10.1021/acs.molpharmaceut.0c00529] [Reference Citation Analysis]
20 Ninfole E, Pinto C, Benedetti A, Marzioni M, Maroni L. Role of autophagy in cholangiocarcinoma: Pathophysiology and implications for therapy. World J Clin Cases 2021; 9(22): 6234-6243 [PMID: 34434990 DOI: 10.12998/wjcc.v9.i22.6234] [Reference Citation Analysis]
21 Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma. Hepatology 2021;73:2380-96. [PMID: 33222246 DOI: 10.1002/hep.31642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Lapitz A, Arbelaiz A, O'Rourke CJ, Lavin JL, Casta A, Ibarra C, Jimeno JP, Santos-Laso A, Izquierdo-Sanchez L, Krawczyk M, Perugorria MJ, Jimenez-Aguero R, Sanchez-Campos A, Riaño I, Gónzalez E, Lammert F, Marzioni M, Macias RIR, Marin JJG, Karlsen TH, Bujanda L, Falcón-Pérez JM, Andersen JB, Aransay AM, Rodrigues PM, Banales JM. Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells 2020;9:E721. [PMID: 32183400 DOI: 10.3390/cells9030721] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
23 Manzia TM, Parente A, Lenci I, Sensi B, Milana M, Gazia C, Signorello A, Angelico R, Grassi G, Tisone G, Baiocchi L. Moving forward in the treatment of cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(12): 1939-1955 [DOI: 10.4251/wjgo.v13.i12.1939] [Reference Citation Analysis]
24 Efferth T, Oesch F. Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities. Semin Cancer Biol 2020:S1044-579X(20)30034-1. [PMID: 32027979 DOI: 10.1016/j.semcancer.2020.01.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
25 Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol 2020; 26(33): 4900-4918 [PMID: 32952338 DOI: 10.3748/wjg.v26.i33.4900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
26 Tantau AI, Mandrutiu A, Pop A, Zaharie RD, Crisan D, Preda CM, Tantau M, Mercea V. Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies. World J Hepatol 2021; 13(2): 166-186 [PMID: 33708349 DOI: 10.4254/wjh.v13.i2.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
27 Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, Vaquero J, Marin JJG, Coulouarn C. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39 Suppl 1:43-62. [PMID: 30903728 DOI: 10.1111/liv.14102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
28 Muhamad P, Panrit L, Chaijaroenkul W, Na-Bangchang K. Cytotoxicity, Cell Cycle Arrest, and Apoptosis Induction Activity of Ethyl-p-methoxycinnamate in Cholangiocarcinoma Cell. Asian Pac J Cancer Prev 2020;21:927-34. [PMID: 32334452 DOI: 10.31557/APJCP.2020.21.4.927] [Reference Citation Analysis]
29 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yapasert R, Lertprasertsuk N, Subhawa S, Poofery J, Sripanidkulchai B, Banjerdpongchai R. Antitumor Efficacy of the Herbal Recipe Benja Amarit against Highly Invasive Cholangiocarcinoma by Inducing Apoptosis both In Vitro and In Vivo. Int J Mol Sci 2020;21:E5669. [PMID: 32784671 DOI: 10.3390/ijms21165669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Marin JJG, Macias RIR, Monte MJ, Herraez E, Peleteiro-Vigil A, Blas BS, Sanchon-Sanchez P, Temprano AG, Espinosa-Escudero RA, Lozano E, Briz O, Romero MR. Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers (Basel) 2020;12:E2605. [PMID: 32933095 DOI: 10.3390/cancers12092605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
32 Marin JJ, Macias RI. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opin Investig Drugs 2021;30:675-9. [PMID: 33934687 DOI: 10.1080/13543784.2021.1916912] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Hu F, Liu C, Xie F, Lin X, Yang J, Wang C, Huang Q. MSI2 knockdown represses extrahepatic cholangiocarcinoma growth and invasion by inhibiting epithelial-mesenchymal transition. Onco Targets Ther 2018;11:4035-46. [PMID: 30034243 DOI: 10.2147/OTT.S170739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Marin JJG, Prete MG, Lamarca A, Tavolari S, Landa-Magdalena A, Brandi G, Segatto O, Vogel A, Macias RIR, Rodrigues PM, Casta A, Mertens J, Rodrigues CMP, Fernandez-Barrena MG, Da Silva Ruivo A, Marzioni M, Mentrasti G, Acedo P, Munoz-Garrido P, Cardinale V, Banales JM, Valle JW, Bridgewater J, Braconi C; working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA). Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 2020;123:1047-59. [PMID: 32694694 DOI: 10.1038/s41416-020-0987-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
35 Lertsuwan K, Phoaubon S, Tasnawijitwong N, Lertsuwan J. Adenosine Suppresses Cholangiocarcinoma Cell Growth and Invasion in Equilibrative Nucleoside Transporters-Dependent Pathway. Int J Mol Sci 2020;21:E814. [PMID: 32012688 DOI: 10.3390/ijms21030814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Di Giacomo S, Briz O, Monte MJ, Sanchez-Vicente L, Abete L, Lozano E, Mazzanti G, Di Sotto A, Marin JJG. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Arch Toxicol 2019;93:623-34. [PMID: 30659321 DOI: 10.1007/s00204-019-02395-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
37 Kim DH, Im BN, Hwang HS, Na K. Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment. Biomaterials 2018;183:139-50. [PMID: 30170256 DOI: 10.1016/j.biomaterials.2018.08.052] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
38 Saengboonmee C, Sawanyawisuth K, Chamgramol Y, Wongkham S. Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Expert Rev Anticancer Ther 2018;18:579-92. [PMID: 29676221 DOI: 10.1080/14737140.2018.1467760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
40 Zhao X, Wen F, Wang W, Lu Z, Guo Q. Actinidia arguta (Hardy Kiwi) Root Extract Exerts Anti-cancer Effects via Mcl-1-Mediated Apoptosis in Cholangiocarcinoma. Nutr Cancer 2019;71:246-56. [PMID: 30633583 DOI: 10.1080/01635581.2018.1557218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Lozano E, Macias RI, Monte MJ, Asensio M, Carmen S, Sanchez‐vicente L, Alonso‐peña M, Al‐abdulla R, Munoz‐garrido P, Satriano L, O'rourke CJ, Banales JM, Avila MA, Martinez‐chantar ML, Andersen JB, Briz O, Marin JJ. Causes of hOCT1‐Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor‐Selective Gene Therapy. Hepatology 2019;70:1246-61. [DOI: 10.1002/hep.30656] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
42 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Reference Citation Analysis]
43 Sun Q, Dong X, Shang Y, Sun F, Niu J, Li F. Integrin αvβ6 predicts poor prognosis and promotes resistance to cisplatin in hilar cholangiocarcinoma. Pathol Res Pract 2020;216:153022. [PMID: 32534716 DOI: 10.1016/j.prp.2020.153022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Marin JJ, Briz O, Herraez E, Lozano E, Asensio M, Di Giacomo S, Romero MR, Osorio-padilla LM, Santos-llamas AI, Serrano MA, Armengol C, Efferth T, Macias RI. Molecular bases of the poor response of liver cancer to chemotherapy. Clinics and Research in Hepatology and Gastroenterology 2018;42:182-92. [DOI: 10.1016/j.clinre.2017.12.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
45 Di Sotto A, Di Giacomo S, Rubini E, Macone A, Gulli M, Mammola CL, Eufemi M, Mancinelli R, Mazzanti G. Modulation of STAT3 Signaling, Cell Redox Defenses and Cell Cycle Checkpoints by β-Caryophyllene in Cholangiocarcinoma Cells: Possible Mechanisms Accounting for Doxorubicin Chemosensitization and Chemoprevention. Cells 2020;9:E858. [PMID: 32252311 DOI: 10.3390/cells9040858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Neureiter D, Mayr C, Kiesslich T. How do we choose the appropriate chemotherapeutic agents for biliary tract cancer? Expert Opin Pharmacother 2020;21:243-5. [PMID: 31899989 DOI: 10.1080/14656566.2019.1705280] [Reference Citation Analysis]
47 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Reference Citation Analysis]
48 Kittirat Y, Phetcharaburanin J, Promraksa B, Kulthawatsiri T, Wangwiwatsin A, Klanrit P, Sangkhamanon S, Jarearnrat A, Thongchot S, Mahalapbutr P, Loilome W, Saya H, Namwat N. Lipidomic Analyses Uncover Apoptotic and Inhibitory Effects of Pyrvinium Pamoate on Cholangiocarcinoma Cells via Mitochondrial Membrane Potential Dysfunction. Front Public Health 2021;9:766455. [DOI: 10.3389/fpubh.2021.766455] [Reference Citation Analysis]
49 Wu J, Sheng J, Qin H, Cui M, Yang Y, Zhang X. The Application Progress of Patient-Derived Tumor Xenograft Models After Cholangiocarcinoma Surgeries. Front Oncol 2021;11:628636. [PMID: 34367944 DOI: 10.3389/fonc.2021.628636] [Reference Citation Analysis]
50 Mostafazadeh M, Samadi N, Kahroba H, Baradaran B, Haiaty S, Nouri M. Potential roles and prognostic significance of exosomes in cancer drug resistance. Cell Biosci 2021;11:1. [PMID: 33407894 DOI: 10.1186/s13578-020-00515-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
51 Mancinelli R, Mammola C, Sferra R, Pompili S, Vetuschi A, Pannarale L. Role of the Angiogenic Factors in Cholangiocarcinoma. Applied Sciences 2019;9:1393. [DOI: 10.3390/app9071393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
52 Di Sotto A, Mancinelli R, Gullì M, Eufemi M, Mammola CL, Mazzanti G, Di Giacomo S. Chemopreventive Potential of Caryophyllane Sesquiterpenes: An Overview of Preliminary Evidence. Cancers (Basel) 2020;12:E3034. [PMID: 33081075 DOI: 10.3390/cancers12103034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
53 Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, Wu C, Chakraborty S, Glaser S, Alpini G. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs 2021;30:365-75. [PMID: 33226854 DOI: 10.1080/13543784.2021.1854725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]